pharmaceutical consultancy

Apr 18, 2018

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...

Jan 19, 2018

Familial Amyloid Polyneuropathy (also known as transthyretin amyloidosis, TTR, and FAP) is a group of endangering multisystem disorders which are transmitted as an autosomal dominant trait. It is caused by the excessive accumulation of amyloid in the organs and tissues. The first identified cause of FAP is the Val30...

Jan 08, 2018

Hereditary Angioedema (HAE) is an autosomal dominant disease which is caused by a deficiency in functional C1 inhibitor. It is a rare hereditary disease which is characterized by painful, unpredictable, recurrent attacks of inflammation and swelling affecting the hands, feet, face, abdomen, urogenital tract, and the...